Abstract
Heart failure (HF) is a serious, chronic disease, causing significant ill health and high mortality worldwide. The current clinical strategies emphasize reducing the transition from a healthy to a failing heart despite the shift in the clinical goal from healing to disease prevention. Recent research advancements on noncoding RNAs (ncRNAs) have demonstrated that circular RNAs (circRNAs) are significant therapeutic targets in HF. Previous studies have highlighted the potential applicability of circRNAs in the diagnosis and treatment of diseases. However, less is known regarding the potential benefits of circRNAs as novel diagnostic and treatment biomarkers for HF. In the present study, we summarize the current developments and achievements associated with the use of circRNAs as HF biomarkers. We also discuss future research directions regarding HF diagnosis and treatment.
Highlights
Heart failure (HF) is attributed to several cardiovascular diseases (CVDs), including, cardiac hypertrophy, myocardial fibrosis, and ischemic cardiomyopathy
Circ_LAS1L sponged miR125b to upregulate the expression of secreted frizzled-related protein 5 (SFRP5) and inhibit the expression of a-SMA, collagen I, and collagen III to play an important role in the process of myocardial fibrosis (MF)
These findings demonstrate that circRNAs have potential regulatory functions in HF and inhibit symptoms that can induce HF, including hypertrophy, cardiomyocyte apoptosis, and ventricular remodeling
Summary
Heart failure (HF) is attributed to several cardiovascular diseases (CVDs), including, cardiac hypertrophy, myocardial fibrosis, and ischemic cardiomyopathy. Hypertension and coronary heart disease are reported as the main causes of HF in China, and infections have been implicated in the pathogenesis of HF. Patients with HF present with nonspecific symptoms and are difficult to distinguish from those of other cardiovascular diseases. Some of the symptoms presented by patients with HF include dyspnea, orthopnea, and paroxysmal nocturnal dyspnea. Accurate and effective diagnostic measures are needed in clinical practice to distinguish HF from other cardiovascular diseases. CircRNA Biomarker in Heart Failure ventricular ejection fraction, diastolic function, and chamber pressures that may help diagnose HF. Patients with asymptomatic HF have ventricular diastolic dysfunction and abnormal ejection fraction with no accompanying clinical symptoms (Naji et al, 2017), further complicating HF diagnosis. The development of novel biomarkers can predict and diagnose HF, risk stratification of patients with HF, and even serve as therapeutic targets are of biological significance (Gaggin and Januzzi, 2013)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
